Beyond these common adverse events, GLP‐1 RAs have been linked to more serious conditions such as pancreatitis, with a risk reportedly nine times higher than that associated with older weight‐loss medications like bupropion, although the absolute risk remains below 1% annually [36]. The gene discussed is GLP1R; the disease is pancreatitis.